A Japanese government panel of specialists has endorsed Sumitomo Pharma's iPS cell-derived treatment for Parkinson's disease — paving the way for the world's first approved medical product based on induced pluripotent stem cell technology. The therapy, AMCHEPRY, transplants dopaminergic neuron precursors derived from iPS cells into the brains of Parkinson's patients. This landmark decision validates a technology pioneered by Nobel laureate Shinya Yamanaka nearly two decades ago and opens a new chapter in regenerative medicine.
Today's PDUFA date for a new therapy in platinum-resistant recurrent ovarian cancer — one of the most difficult-to-treat gynecologic malignancies. One of five key oncology FDA decisions in Q1 2026.
Zealand reports full-year 2025 results and declares 2026 "catalyst-rich." The historic Roche partnership for GLP-1/amylin agonist petrelintide and strong pipeline progress position the Danish biotech as a major obesity/metabolism player.
IBRX stock trading near $8.68 — up 100% year-to-date and nearly tripled from 2025 lows. A string of international regulatory wins for bladder cancer immunotherapy ANKTIVA is fueling the rally. Immunotherapy 2.0 thesis in action.
The active pharmaceutical ingredients market is projected to grow from $252B in 2026 to $425B by 2035 at 5.95% CAGR — driven by biosimilars, complex generics, and reshoring of manufacturing capacity.
Day 4 of India's AI Impact Summit 2026 — the first international AI summit hosted in the Global South. Sam Altman told delegates the cost of AI will "fall dramatically," while Reliance/Jio announced a ₹10 lakh crore (~$120B) investment in sovereign AI compute over seven years, with 120+ MW of capacity coming online in Jamnagar this year. PM Modi called for "inclusive technology for everyone." Over 100 nations, 50+ ministers and 40 CEOs attended the week-long event at Bharat Mandapam, New Delhi.
The Guardian launches "Reworked," a year-long reporting series centering human stakes as AI disrupts workplaces. The opening essay explores how uncertainty is driving organizing impulses not seen since the early labor movement.
Reports confirm ChatGPT maker OpenAI is finalizing a $100B round — the largest private funding in history. The unprofitable startup has committed to spending hundreds of billions on compute capacity over the coming years. Big tech stocks were mixed on the news.
The U.S. Supreme Court has added Friday, February 20 as a decision day — the first opportunity in weeks to issue a verdict on the closely watched challenge to Trump's sweeping "reciprocal tariffs" under the International Emergency Economic Powers Act. The Tax Policy Center estimates a ruling against IEEPA tariffs would save households an average of $1,200 in 2026 and cut taxes by $1.4 trillion over 10 years. Retailers and furniture makers brace for impact regardless: some sector-specific duties will persist.
Dow fell 0.5%, S&P 500 and Nasdaq each slipped 0.3%. Oil prices rose to a six-month high on escalating U.S.–Iran tensions. Walmart slid 1.5% despite strong sales; Carvana tanked 8% on profitability miss. Asian equities edged lower overnight.
Rising fuel costs from the Iran-driven oil spike are pressuring airline earnings. American Airlines' 10-K filing and an upcoming safety vote added caution. Investors watching whether margins can survive $85+ crude.
Motley Fool2 min
YTDS&P 500 +0.2% · Dow +2% · Nasdaq –2% — tech lagging in 2026 so far
OilCrude at 6-month high on U.S.–Iran escalation · Brent above $85
With the trade deadline in the rearview, attention shifts to the buyout market. Players must be waived by March 1 to retain playoff eligibility. Khris Middleton (Dallas) is the biggest name — Boston (missing Tatum to Achilles rehab) and the Knicks are circling. The Warriors, fresh off acquiring Kristaps Porzingis from Atlanta, could still add a veteran wing. Lonzo Ball remains a wildcard. Every contender is making calls.
Anthony Davis shipped from Dallas to Washington in a three-team deal. Indiana gets Zubac and will add Haliburton back from Achilles rehab. The Pacers are building a Finals-caliber squad around a loaded 2026 draft pick. Meanwhile, Cleveland's Harden bet is all-or-nothing.
HoopsHype ranks the top available free agents this summer. LeBron James leads the list at 41. Austin Reaves, James Harden (player option), and Trae Young round out a loaded class that could reshape the league.